Repligen Newsroom

Repligen Analyst Ratings

BenzingaJun 26 18:33

Deutsche Bank Upgrades Repligen to Buy, Lowers Price Target to $155

BenzingaJun 26 18:32

RBC Cuts Price Target on Repligen to $190 From $221, Maintains Outperform Rating

MT NewswiresJun 24 18:32

Repligen Analyst Ratings

BenzingaJun 18 18:45

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Repligen (RGEN) and Agenus (AGEN)

TipRanksMay 3 19:50

JP Morgan Maintains Overweight on Repligen, Lowers Price Target to $200

BenzingaMay 3 00:50

Repligen Analyst Ratings

BenzingaMay 3 00:45

UBS Adjusts Price Target on Repligen to $205 From $225, Maintains Buy Rating

MT NewswiresMay 2 23:33

Repligen (RGEN) Gets a Buy From RBC Capital

TipRanksMay 1 09:50

Craig-Hallum Sticks to Their Buy Rating for Repligen (RGEN)

TipRanksApr 29 21:01

RBC Capital Remains a Buy on Repligen (RGEN)

TipRanksApr 9 09:51

RBC Cuts Price Target on Repligen to $221 From $225, Keeps Outperform Rating

MT NewswiresApr 8 19:57

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immuneering (IMRX), Halozyme (HALO) and Repligen (RGEN)

TipRanksFeb 26 13:10

Repligen Analyst Ratings

BenzingaFeb 23 03:03

Deutsche Bank Adjusts Repligen Price Target to $180 From $175, Maintains Hold Rating

MT NewswiresFeb 23 00:22

RBC Raises Price Target on Repligen to $225 From $200, Keeps Outperform Rating

MT NewswiresFeb 22 20:43

Repligen (RGEN) Receives a Buy From RBC Capital

TipRanksFeb 22 20:31

Repligen (RGEN) Gets a Buy From Craig-Hallum

TipRanksFeb 20 21:39

Keybanc Maintains Overweight on Repligen, Raises Price Target to $220

BenzingaFeb 16 03:14

Repligen Analyst Ratings

BenzingaFeb 16 03:12